Considering Bladder Control Therapy

Why Are Medtronic Therapies Different?

Communication Is Critical

Evidence suggests that breakdowns in the bladder-brain communication pathway are a root cause of OAB and non-obstructive urinary retention.1-3 While more conservative therapies focus on the bladder muscles, Medtronic therapies target the nerves that control the bladder muscles, which are thought to help restore normal bladder function.*

diagram of brain and kidneys on how bladder works

Interstim X™ System

Interstim x device next to quarter


  • Recharge-free battery
  • Battery life: more than 10 years||
  • Device size: 12.5 cm3
  • No routine maintenance
  • SureScan™ MRI technology allows 1.5 and 3T full-body scans when certain conditions are met§


  • Smart programmer, communicator

Interstim™ Micro System

Interstim Mircro next to quarter


  • Rechargeable battery with OverdriveTM technology
  • Battery life: 15 years
  • Device size: 2.8 cm3
  • Weekly recharging in approximately 20 minutes
  • SureScan™ MRI technology allows 1.5 and 3T full-body scans when certain conditions are met§


  • Smart programmer, communicator, recharger, charging dock, recharging belt
Several Interstim devices

Implanting an InterStim™ system has risks similar to any surgical procedure, including swelling, bruising, bleeding, and infection. Talk with your doctor about ways to minimize these risks.

Lasting Relief, at Last

Medtronic bladder control therapy delivered by the InterStim™ systems provides life-changing relief.

  • 84% satisfaction among those who use it#,7
  • 76% of people achieved success at 6 months compared to 49% who used medications**,6

The most common adverse events experienced during clinical studies included pain at implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations. Any of these may require additional surgery or cause return of symptoms.

Medtronic Bladder Control Therapy Delivered by the Nuro™ System

Medtronic bladder control therapy delivered by the NURO™ system helps you live with less worry and more confidence. By restoring bladder function, it puts you on a path to fewer trips to the bathroom, and more of the activities you enjoy.‡‡,9

  • Targets the tibial nerve to help you regain control of your bladder
  • Does not cause unpleasant side effects like many oral medications can10
  • Does not require self-catheterization, unlike injectable medications8
  • Helps you live with less worry and more confidence

The NURO™ system only treats the symptoms of OAB, not retention.

Most common side effects of PTNM are temporary and include mild pain or skin inflammation at or near the stimulation site.

Nuro Device

Start the Conversation

Talking about bladder control problems can be difficult. But this doctor discussion guide can help you get through it more easily.

What Is Bladder Control Therapy?

Read a quick overview to understand your options and see if Medtronic bladder control therapy might be right for you.

Visualize Your Journey

The care pathway helps you understand all of the treatment options available for bladder control problems.

Defined as a 50% or greater reduction in your troublesome bladder symptoms.

Numbers reflect completers analysis defined as patients with diary data at baseline and 12 months (n=220). Clinical success was 82% at 12 months using the modified completers analysis (subjects who either had a baseline and 12 month evaluation or withdrew early due to device-related reasons and are considered failures).

anticholinergic/antimuscarinic medication

§Under certain conditions. See approved labeling for details. Patients with InterStim™ SureScan™ MRI leads only.

||Under expected therapy settings and telemetry use.

Under standard patient therapy settings and appropriate recharger placement.

# Reflects OAB patients.

**These patient groups were analyzed based on the treatment they were assigned: incomplete data was counted as ”failures.” Another analysis reported 61% of people achieved success with InterStim, compared to 42% who used medications.

††The MID (minimally important difference) is the smallest score change that is perceived beneficial to patients and is often used to determine whether changes in scores are considered clinically significant.

‡‡Restored bladder function is defined as a measurable reduction in urinary frequency and/or urinary incontinence episodes following treatment.

1Dasgupta R, Critchley HD, Dolan RJ, Fowler CJ. Changes in brain activity following sacral neuromodulation for urinary retention. J Urol. 2005;174:2268–2272.

2Griffiths D, Derbyshire S, Stenger A, Resnick N. Brain control of normal and overactive bladder. J Urol. 2005;174:1862–1867.

3Griffiths D, Tadic SD. Bladder control, urgency, and urge incontinence: evidence from functional brain imaging. Neurourol Urodyn. 2008;27(6):466–474.

4Noblett K, Siegel S, Mangel J, et al. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. Neurourol Urodyn. 2016 Feb;35(2):246–51.

5National Association for Continence. Overactive Bladder. new window). Accessed November 21, 2016.

6Siegel S, Noblett K, Mangel J, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim® Therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015;34:224–230.

7Foster RT Sr, Anoia EJ, Webster GD, Amundsen CL. In patients undergoing neuromodulation for intractable urge incontinence a reduction in 24-hour pad weight after the initial test stimulation best predicts long-term patient satisfaction. Neurourol Urodyn. 2007;26:213–217.

8Visco A, Brubaker L, Richter HE, et al. Anticholinergic therapy versus onabotulinumtoxinA for urgency urinary incontinence. New Engl J Med. 2012;367(19):1803–1813.

9Peters KM, Carrico DJ, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183(4): 1438–1443.

10Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182(3):1055–1061.

Information on this site should not be used as a substitute for talking with your doctor. Always talk with your doctor about diagnosis and treatment information.